Duhao Net

Duhao Net helps individual entrepreneurs and enterprises find high-quality suppliers, reduce procurement costs, and make transactions easier.

DongBang Future Tech & Life Co., Ltd.: natural APIs, health functional foods, and finished pharmaceuticals

Release time：2025-06-27 23:23:32 Source：DuHao

Contact Us Today

Tel : +82 031-354-1114

Email: net.fei@163.com

Address: 78, Yakjakgongdan 4-gil, Hyangnam-eup, Hwaseong-si, Gyeonggi-do, Korea.

Founded in 1990, DongBang FTL is a leading global pharmaceutical company dedicated to advancing human health and well-being through innovative, high-quality pharmaceuticals. Guided by our corporate philosophy—“contributing to the happiness and health of mankind with the highest-quality pharmaceuticals”—we have expanded our expertise from synthetic active pharmaceutical ingredients (APIs) to natural APIs, health functional foods, and finished pharmaceuticals.

Over the past three decades, we have earned international recognition for our manufacturing excellence, securing prestigious certifications including EU-GMP (France ANSM), Japan GMP (PMDA), and Australia GMP (TGA). Today, we specialize in CMC (Chemistry, Manufacturing, and Controls) and CDMO (Contract Development and Manufacturing Organization) services, partnering with global biopharmaceutical firms, startups, and research institutes to drive innovation in drug development.

Core Business Areas

1. Synthetic APIs

DongBang FTL is a trusted supplier of high-purity synthetic APIs, serving global markets with products in therapeutic areas such as:

  • Anti-inflammatory analgesics

  • Hypertension & cardiovascular disease treatments

  • Diabetes & urinary system medications

Our 20+ Japan DMF and 10+ EU-DMF filings underscore our strong presence in regulated markets. We also lead in HPAPI (Highly Active Pharmaceutical Ingredients) production, with specialized facilities for compounds requiring OEB Level 3+ containment.

2. Natural APIs & Herbal Medicines

A pioneer in Korean herbal medicine GMP certification, we invest heavily in novel botanical drug development. Key projects include:

  • HBX-6: A Phase 2 clinical-stage treatment for benign prostatic hyperplasia, derived from traditional medicine (Donguibogam).

  • Keratin-based hair loss treatment: An injectable API under preclinical development.

  • Patented health functional food ingredients.

3. Finished Pharmaceuticals

Our finished dosage forms (tablets, soft/hard capsules) cover:

  • Anti-inflammatory drugs

  • Neurological disorder treatments

  • Vitamins & supplements
    Marketed domestically and internationally via OEM/ODM partnerships.

Innovation & Future Growth

PROTAC Technology

As early adopters of PROTAC (PROteolysis TArgeting Chimera), we are redefining drug discovery by developing:

  • Target protein degraders with 150+ building blocks.

  • Proprietary E3 ligases and linkers for next-generation therapeutics.

Hybrid Small-Molecule Drugs

Leveraging AI-driven molecular design, we engineer multi-target drugs to address complex diseases, accelerating candidate selection and scale-up under GMP.

Open Innovation Center (OIC)

Our OIC collaborates with academia and startups to commercialize breakthroughs, offering:

  • AI-based molecular design & synthesis support.

  • Scale-up and GMP manufacturing for preclinical/clinical materials.

  • Bioassay partnerships for validation.

Global Impact & Social Responsibility

In 2022, DongBang FTL was selected by the UN’s Medicines Patent Pool (MPP) to produce generic APIs for Pfizer’s Paxlovid® (Nirmatrelvir/Ritonavir) and MSD’s Lagevrio® (Molnupiravir)—critical COVID-19 treatments for low- and middle-income countries. This milestone reflects our commitment to global health equity and technological leadership.

Vision

DongBang FTL continues to pioneer the future of biopharma through cutting-edge R&D, strategic collaborations, and sustainable growth—always striving to deliver “the highest quality for humanity’s health.”

DuHao Net